ELEVATE High-Risk PCI Pivotal Study

Recruiting N/A Interventional Study
High-Risk Percutaneous Coronary Intervention (High-risk PCI)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 88
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
290 (estimated)
Sponsor
Magenta Medical Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The ELEVATE III Pivotal Study is a prospective, multi-center, open-label, interventional, randomized, controlled study with an active control group. The study is intended to assess the safety and efficacy of the Elevate™ percutaneous Left Ventricular Assist Device System in patients referred to high-risk percutaneous coronary interventions (HR-PCI).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Non-emergent, percutaneous coronary intervention is planned on at least one stenotic lesion of a native coronary artery or bypass graft (de novo or restenosis). 2. A heart team that includes an interventional cardiologist and cardiac surgeon has determined that HR- PCI is an …
Contacts

No contact information available.